

GE Healthcare Driving Innovation

Tom Gentile
President & CEO
GE Healthcare Systems

Deutsche Bank Conference
13 June 2013



GE imagination at work



GE Healthcare

~\$20 billion global business unit of GE

53,000 employees worldwide

~\$1 billion/year investment in R&D

Leading technologies


Healthyagination focused on:



Affordability



Improved quality



Increased access

Healthcare Systems



Main products

MI CT DGS



MR U/S



LCS Services

Rev. \$14B

Life Sciences



Main products

Bioprocess



Cell technologies

Research



Consumables

Rev. \$2B

Healthcare IT



Main products

PACS



RIS



Ambulatory EMR

Caradigm (MS JV)


Rev. \$2B

Medical Diagnostics



Main products

PET/SPECT Tracers



Clarent/Pathology

Genomics



Rev. \$2B

Healthcare trends

Biomarkers and genomics



Patient Experience




Globalization



Minimally invasive procedures



Monitoring therapies




Mobility and connectivity



Insights driving product innovation

GE plays across breast care continuum




“Connecting” across modalities

* No FDA organ-specific indications for breast
 ** Product under development. Omnyx products are for research only. Not for use in diagnostic procedures.

Global healthcare structural dynamics


Healthcare spend by country



New growth less concentrated, more complex

Geographical diversity

(\$ in billions)



- ✓ Expect slow growth in developed markets
 - Aligned sales force to win with the winning customers
 - Focus on cross selling & solutions
 - Rightsizing enabling functions
- ✓ Emerging markets continue to show strength
 - Expand coverage
 - More locally developed products ... more added value
 - Opportunity to partner with governments

Winning in emerging markets key driver of growth

Our purpose... a reminder



At work for a healthier world